Baird Financial Group
PETX

Baird Financial Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Baird Financial Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-44,344
Closed -$233K – 1330
2017
Q4 		$233K Sell
44,344
-1,056
-2% -$6.46K ﹤0.01% 1181
2017
Q3 		$278K Buy
45,400
+987
+2% +$6.25K ﹤0.01% 1121
2017
Q2 		$321K Buy
44,413
+3,655
+9% +$22.5K ﹤0.01% 1069
2017
Q1 		$216K Buy
40,758
+9,880
+32% +$66.7K ﹤0.01% 1148
2016
Q4 		$222K Buy
30,878
+1,659
+6% +$13.4K ﹤0.01% 1120
2016
Q3 		$273K Buy
29,219
+18
+0.1% +$149 ﹤0.01% 1076
2016
Q2 		$198K Buy
+29,201
New +$188K ﹤0.01% 1143

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Baird Financial Group's PETX Position: Q1 2018 in Review

Baird Financial Group sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 44,344 shares — an estimated $233K sold.

Baird Financial Group first reported a position in PETX in Q2 2016 and held it in 7 quarters. The position peaked at $321K in Q2 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Baird Financial Group reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Baird Financial Group sold 44,344 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $233K.
  • Baird Financial Group first reported a position in Aratana Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
  • Baird Financial Group's Aratana Therapeutics, Inc. position peaked at $321K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Baird Financial Group's 13F filing for Q1 2018, filed 14 May 2018.